about
The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research.Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer.The comprehensive care project: measuring physician performance in ambulatory practicePerioperative goal-directed therapy and postoperative outcomes in patients undergoing high-risk abdominal surgery: a historical-prospective, comparative effectiveness study.Flaws in mortality data. The hazards of ignoring comorbid disease.Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment.The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatmentA framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity.A remote monitoring and telephone nurse coaching intervention to reduce readmissions among patients with heart failure: study protocol for the Better Effectiveness After Transition - Heart Failure (BEAT-HF) randomized controlled trialHealth status assessment for elderly patients. Report of the Society of General Internal Medicine Task Force on Health Assessment.The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort.Cost Variation Within Spinal Fusion Payment Groups.Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease.Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice.The use of an ROC curve to express quality of care results.Predicting the Risk of Breakthrough Urinary Tract Infections: Primary Vesicoureteral Reflux.The next generation of research in provider optimization.Cancer survivorship care for the general internist: have we paved the way for a smoother transition?Quality of care--how good is good enough?The relationship between physicians' self-reported target fasting blood glucose levels and metabolic control in type 2 diabetes. The QuED Study Group--quality of care and outcomes in type 2 diabetes.The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies.Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked.Quality of care and outcomes in type 2 diabetic patients: a comparison between general practice and diabetes clinics.Comorbidity and competing risks for mortality in men with prostate cancer.Making Real-World Evidence More Useful for Decision Making.The complexities of comparative effectiveness research on devices: the case of robotic-assisted surgery for prostate cancer.The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study.Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes.Observational studies versus randomized trials: squaring off.Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.Clinical Practice Guidelines: Expanded Use and Misuse.The Patient's role in reducing disparities.Differences in the mix of patients among medical specialties and systems of care. Results from the medical outcomes study.When Clinical Practice Guidelines Collide: Finding a Way Forward.Self-monitoring of blood glucose in non-insulin-treated diabetic patients: a longitudinal evaluation of its impact on metabolic control.Guideline Recommendations for Preventive Healthcare Services: Understanding and Managing Conflict of Interest When Population Health Meets Personalized Medicine.The Effect of Nerve Sparing Status On Sexual and Urinary Function: 3-Year Results from the CEASAR Study.Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
P50
Q27311513-DF2C479C-3E55-4B8E-A112-BB94AFC70072Q33873170-3D333C69-DB05-49CB-9803-F327337563CFQ34534624-AD31B979-BE6F-4C78-912F-0C2AC46BA62DQ35881484-15F21353-2345-47D2-A7E4-A040DC793CB3Q36436512-CB84AB32-2384-4FC0-838A-FDDA2E0BAC33Q36778059-ED2D5442-60A9-4E0F-A5AC-C4E44C06C676Q37028549-DD47DCBA-5603-461E-B75E-E473CD3E5F82Q37059743-A80048C8-4EE7-4BC7-A1C7-04133D8BA02DQ37663077-3285E036-F51A-4344-A03E-3E059F2F750CQ37708102-3F63D611-662A-4E4A-9D93-16BA9ADD84A0Q38626633-70FA479D-39C8-4227-8746-7E5BC5678797Q38758510-A3EDA828-3B36-4DCD-8A75-A83DA3C1A3E6Q38876378-037C46BC-A227-4837-8FE3-68BE743617C8Q38890085-18B74379-CCA9-4A10-96E3-AFCFC8B4AE51Q39510425-FF94D3FD-68DF-449E-A4D4-FCA2AC850250Q40234711-A8C67CFC-3E7F-4938-9591-748331A6B2B7Q40347291-3EB4ECBA-B2EE-4531-8908-7855C40AAE83Q41168386-E46EBD92-61ED-44D0-81F4-902904551E4BQ42341900-87C4378E-FC0F-429D-B2B5-23B21128DEF3Q42585294-557F80D6-416E-43C1-958C-433DE4A83581Q43500361-273C52EA-14F4-4B89-B369-AC35B660FA8EQ43566512-DBCCBD0F-FFFA-49E2-97F4-060859E375D8Q43778832-2468BE95-1F46-4D6D-A72B-FDF18E17CBBBQ44131717-451DDE52-B238-4BFE-9C61-667E6762BC6EQ44745026-9A4E5411-83FD-4BED-8B7D-D7C98AF4B75FQ45064053-9114AB9C-F3F3-4C9F-8875-D44B721B1CEFQ45946637-951B1A80-BF5A-46BF-BF11-BE3F34BF414EQ46031036-3CFB6ED2-E007-44FC-8775-7323DF2CBC06Q46048814-61FDC61F-CA65-42E6-8626-D8A4F91D41DBQ46070566-B28B2EE6-8227-4709-8E4A-C72AEE66AB97Q46078871-D5B10A5C-5C36-49B5-A8C7-9D92C786987FQ46082804-3BCA4565-B0BD-41FD-A858-9E781A57D27BQ46083801-7BE998E0-0399-4EA3-9FFE-D081BF631810Q46192528-573DDD4A-5147-478E-B6F7-F52A85B44E8BQ46247008-7D4A24FB-E279-4440-A841-266E44EEAD1AQ46447747-0055ABAA-BCC2-40EA-AC96-860084F0089AQ46563578-CE490AFF-7ACB-4439-B30F-67A0FEB6CE21Q49647726-90A9C567-25CD-4FD0-A8A2-8A5953E7A171Q49662807-558E76BE-CC1E-49A2-8591-748E6649C0CEQ50124344-0FA9F627-508F-4CCD-9648-B75526A68671
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-4628-1998
@en
name
Sheldon Greenfield
@ast
Sheldon Greenfield
@en
Sheldon Greenfield
@es
Sheldon Greenfield
@nl
type
label
Sheldon Greenfield
@ast
Sheldon Greenfield
@en
Sheldon Greenfield
@es
Sheldon Greenfield
@nl
prefLabel
Sheldon Greenfield
@ast
Sheldon Greenfield
@en
Sheldon Greenfield
@es
Sheldon Greenfield
@nl
P108
P106
P108
P31
P496
0000-0003-4628-1998